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SUMMARY.-An autoantibody response against a breast carcinoma tumour
specific neoantigen is described. The antigen, which was present in 6 of 11
breast carcinomata examined, was shown to have similarities to the T antigen
of DNA virus induced animal tumours. In addition a different antigen (or
antigenic determinant) was shown to be present in one breast carcinoma.
This was not strictly tumour specific, being present in lower concentration in
normal breast from the same individual.
THERE is a growing body ofinformation to indicate that some human tumours
possess antigens which are not present in other tissues of the individual bearing
the tumour (Graham and Graham, 1955; Makari, 1955; Burrows, 1958; De
Carvalho, 1960; Finney, Byers and Wilson, 1960; Nairn, Richmond, McEntegart
and Fothergill, 1960; Buttle, Eperon and Kovacs, 1962; Goudie and McCallum,
1962; McKenna, Sanderson and Blakemore, 1962; Nairn, Fothergill, McEntegart
and Richmond, 1962; De Carvalho, Rand and Ashby, 1963; Greenspan, Brown
and Schwartz, 1963; Hodkinson and Taylor, 1969). Such antigens will be
referred to as tumour neoantigens. Autoimmune responses to tumour neo-
antigens appear to be rare (Graham and Graham, 1955; Finney et al., 1960;
Hodkinson and Taylor, 1969; Lewis et al., 1969) and yet clearly antigens which
ought to induce an immune response must be liberated in not inconsiderable
amounts from tumours undergoing necrosis. The work reported here concerns
an autoimmune response to a neoantigen ofbreast carcinoma and the observations
made may explain why such responses are not easily detectable. In addition
studies on the character of the tumour neoantigen suggest its similarity to the
T antigen of oncogenic DNA-virus transformed cells and DNA-virus induced
animal tumours.
MATERIALS AND METHODS
The methods employed have previously been described (Hodkinson and
Taylor, 1969). In essence they consisted of homogenisation (in the proportion of
1 g. tissue in 10 ml. isotonic sucrose solution) of breast carcinoma and corre-
sponding normal breast tissue obtained from surgical specimens, followed by
differential centrifugation. The method of differential centrifugation was that of
Schneider (1948) and gives rise to four fractions termed: nuclear, mitochondrial,
microsomal and supernatant. No attempt was made to assess the degree of
separation of the four cell fractions by electron microscopy, but the degree of
purity of the nuclear fraction was assessed by light microscopy of heavy smearsG. TAYLOR AND J. L. ODILI
stained with haematoxylin and eosin. The four fractions of both normal and
carcinomatous tissue were used as antigens in attempts to detect autoantibodies
in sera taken from the individual providing the tissue. Blocks of both tumour
and normal breast were examined by conventional histological methods to confirm
the diagnosis andto ensure that the normal breast tissue did not contain extensions
of the tumour. Blood was taken on the day before removal of the breast and at
intervals after operation up to 214 days. Sera and tissue fractions were stored
at -25° C. until required. A variety of serological techniques were employed
including complement fixation methods and passive agglutination techniques.
These have been fully described elsewhere (Hodkinson and Taylor, 1969). Sera
from normal individuals were used as controls in all tests. Tissues and sera from
11 patients were studied. All were female and ranged in age from 22 to 81 years
(22, 47, 48, 57, 59, 63, 64, 67, 67, 67, 81 years). Histologically all 11 tumours
were adenocarcinomata.
RESULTS
Autoantibody against tumour neoantigen was detected in the serum of only
one subject (A.P.). This reacted only with the nuclear fraction of the breast
carcinoma and not at all against normal breast from the same individual. The
reaction was best demonstrable using the Fulton and Dumbell (1949) complement
fixation method. Antigen dilutions ranging from 1/4 to 1/100 were tested against
serum dilutions of 1/2 to 1/25. Fixation ofcomplement was found to be optimum
at 1/5 serum dilution with 1/10 antigen but significant fixation of complement was
detectable with serum dilutions of 1/25. The amounts of complement consumed
in the reaction by serum taken at different times and one sample of nuclear
fraction antigen are shown in Table I. Thus patient A.P. produced a brisk
TABLE I.-Fixation of Complement with Sera from A.P. and the Nuclear Fraction
of Her Breast Carcinoma
Serum Units ofcomplement fixed*
1 day pre-operation 138
Day 4 post operation 2 44
Day 10 post operation 2 96
Day 56 post operation 4-31
Day 214 post operation 0 95
* Means of two determinations; serum dilution 1/5; antigen dilution 1/10.
circulating antibody response following removal of her tumour. In all other
10 patients tested no antibody activity directed against tumour fractions could be
detected. Twenty normal human control sera gave uniformly negative results
in all tests.
Further studies using serum A.P.
Serum A.P. was tested by complement fixation against the nuclear fractions
of the other 10 breast carcinomata and corresponding normal breasts. The
nuclear fractions from six subjects gave positive fixation (Table II), the other
four gave negative tests as did all 10 normal breast tissue fractions. Serum A.P.
was tested against the nuclear fractions of 10 assorted adenocarcinomata by
complement fixation. These were derived from stomach (3), rectum (5), colon (1)
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TABLE II.-Fixation ofComplement withSerumfrom A.P. and the NuclearFractions
of Ten Other Breast Carcinomata*
Patient Units ofcomplement fixed
CC. . . 3*30
E.S. . . 3*31
D.H. . . 0
D.B. . . 0
H.H. . . 0
A.K. . . 2*95
I.B. . . 0
M.L. . . 3.75
E.M. . 3*35
M.S. . 3 90
* 1/10 antigen dilutions were tested against 1/5 dilution of 56th day post-operative serum.
and oesophagus (1). All gave uniformly negative tests. In addition the 6 breast
carcinoma nuclear fractions which fixed complement with serum A.P. were tested
against 20 normal human sera and negative results were obtained. Thus 7 of 11
breast carcinomata appear to share a common tumour-specific neoantigen.
The antigen appeared to be closely associated with the nuclear fraction, other
fractions giving completely negative results. Microscopy of the nuclear fraction
showed that approximately 80% consisted ofnuclei andnuclear debris. Chemical
examination of the nuclear fractions of the tumours showed protein contents of
from 174-22-4 mg./ml. (mean 20.2) and DNA concentrations of0-28-0'48 mg./ml.
(mean 0 35). It was therefore decided to investigate the effect of deoxyribo-
nuclease (DNase) and ribonuclease (RNase).
The nuclear fractions of the 7 breast carcinomata which appeared to share a
common tumour neoantigen were incubated with DNase and RNase obtainedfrom
bovine pancreas (BDH) at concentrations of 01 mg./ml. and with control comple-
ment fixation test buffer for varying periods of time either at 4° C., 370 C. or a
combination of both temperatures. The treated antigens were then used in the
complement fixation system with the 56-day serum from A.P. The results are
shown in Table III.
Two points emerge from this experiment. First the tumour neoantigens
appear to be heat-labile at 370 C. in pH 7*4 buffer, losing most ifnot all ability to
fix complement in the presence of antibody after approximately 3-4 hours.
Secondly although six antigens behave in a similar manner being resistant to
RNase and destroyed by DNase, one antigen, C.C., appears to have the reverse
properties and is inactivated by RNase. These unexpected results proved to be
repeatable.
It seems possible therefore that two antigen-antibody systems are being
detected by the serological test used. This was further investigated by cross-
absorption studies in which antigens E.S. (DNase-susceptible) and C.C. (RNase-
susceptible) were compared. Aliquots of serum A.P. were absorbed overnight at
40 C. with nuclear fractions of normal breast and breast carcinoma from E.S. and
C.C. in the ratio of 01 ml. " neat " nuclear fraction (i.e. from 0 04 g. tissue) to
0 4 ml. of 1/4 serum. The absorbed sera were centrifuged at 1000 x g for
15 minutes, decanted and then tested by complement fixation against both the
nuclear fractions ofbreast carcinomata from E.S. and C.C. The results are shown
in Table IVa. Similar absorption studies were carried out with normal breast
and tumour nuclear fractions from patients A.K., M.L., E.M. and M.S. These
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TABLE III.-The Effect of DNase and RNase on
Antigens
Incubation system
A
the Tumour Nucles-associated
Time and temperature
t A
Antigen
A.P.
CC.
E.S.
A.K.
M.L.
E.M.
M.S.
Control
CFT buffer
pH 7-4
2.85*
2 08
0
3 30
1*84
0
3-31
1*47
0-63
2-95
1-52
1.0
3.75
2 70
0
2*84
0 75
2*84
0*25
DNase
2-85
0 77
0
1-85
1'47
0
0
0
0
0
0
0-6
0
0
0
RNase
2-95
2*08
0
0
0-56
0
2 85
1*47
0
2*35
1-47
2*95
2*35
2-84
2*84
* The numbers represent the units of complement fixed using
Minutes Overnight
at 370 C. at 40 C.
0 +
80 +
170 +
80 +
115 -
170 +
80 +
115 -
170 +
80 +
120 +
240 -
80 +
120 -
240 -
120 -
240 -
120 -
240 -
1/5 A.P. serum and 1/10 antigen.
TABLE IVa.-Cross Absorption Studies with DNase and RNase-susceptible Antigens
of Breast Carcinoma
Tested against
nuclear fraction antigen
Serum E.S. C.C.
Unabsorbed . . . . + (3-31) + (3.30)
Absorbed tumour E.S. . - (0.70) + (1.6)
,,. ,, C.C. . . - (0.70) - (0.55)
Absorbed normal breast E.S. + (2.95) + (2.63)
,, ,, ,, 9 C.C. + (1.84) - (0-94)
Notes.The figures in brackets represent units ofcomplement fixed. + and - represent presence
or absence of antibody; fixation of less than 1 unit of complement was considered to be negative.
TABLE IVb.-Absorption ofSerum A.P. with DNase-susceptible Antigens of Breast
Serum
Unabsorbed
Absorbed tumour A.K.
,, oil M.L.
,, 9 ,, E.M.
, M.S.
Absorbed normal breast A.K.
,, ,, ,, M.L.
,, 1,, ,, E.M.
,, ,, ,,1 M.S.
(Carcinoma
Tested against nuclear fraction antigen
A.K. M.L. E.M. M.S.
+ (2.77) + (2*65) + (2.95) + (2.95)
-(0.45) -(0)
-(0) -(0)
-(0) -(0)
-(0) -(0)
(2.53) + (2.41)
+ (2:53) + (2d13)
.. .. ~~~~+ (270) + (.2 75)
+ (2 70) + (2.70)
Notes.-The figures represent units ofcomplement fixed. + and - represent presence or absence
ofantibody; fixation of less than 1 unit ofcomplement was considered to be negative.
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results are shown in Table IVrb and indicate that these antigens behave in a manner
similar to antigen E.S. The implications from these results may be summarised as
follows.
(a) Serum A.P. contains two distinct antibodies capable ofreaction with antigens
present in the breast carcinomata of E.S., A.K., M.L., E.M. and M.S. on the one
hand and carcinoma C.C. on the other.
(b) The DNase and RNase-susceptible antigens share common antigenic deter-
minants but are not identical.
(c) The RNase-susceptible antigen is present both in the carcinoma and normal
breast ofpatient C.C. In the normal breast it is however not detectable by direct
complement fixation but is revealed by absorption methods. This is almost
certainly indicative of a much lower concentration in normal breast as compared
with carcinoma.
(d) The DNase-susceptible antigen of patients E.S., A.K., M.L., E.M. and M.S.
are tumour specific.
(e) A mild but repeatable degree of anti-complementary activity developed
in serum A.P. when absorbed with tumour nuclear fraction E.S. and other DNase
susceptible tumour neoantigens, but not with tumour nuclear fraction from C.C.
nor from any normal breast. The anticomplementary activity ranged from
1-5 uInits to 2-5 units (nean of 14 determinations 1P96 units). The anticomple-
mentary activity could not be removed by centrifugation of a sufficient degree to
deposit the original nuclear fractions (1000 x g for 15 minutes). This observation
suggests that the DNase-susceptible antigen, unlike the RNase-susceptible
antigen, may be capable under some circumstances of dissociation from the heavy
nuclear material and existing in a much less dense or smaller form, and that the
anticomplementary activity is due to soluble antigen-antibody complexes.
Attempts were made to confirm this suggestion by more thorough homogenisation
of the tissue followed by high-speed centrifugation. Sonication, commonly used
in the investigation ofT antigens ofexperimental animal tumours, proved unsatis-
factory possibly due to local heating inactivating the labile antigen. By starting
with a more concentrated material (2 g. tissue in 10 ml. isotonic sucrose solution)
and homogenising by slow thorough grinding with glass fragments the antigen
was not denatured. After clarification by slow-speed centrifugation the extracts
were treated at 100,000 x g for 2 hours in a Spinco model L2 ultracentrifuge.
The supernatant was tested by complement fixation against serum A.P. and it
was demonstrated that the DNase-susceptible antigen was not sedimented by
such high gravitational fields. Thus providing the homogenisation is sufficiently
thorough it is possible to demonstrate that the tumour neoantigen is in the range
ofsize which is usually considered soluble. If on the other hand the homogenisa-
tion is incomplete most of the antigen remains with the nuclei.
DISCUSSION
Autoantibody responses to tumour neoantigens have not been commonly
observed. The reasons for their rarity are not very clear. It has been well
demonstrated that experimental animal tumours possess new antigens, and the
evidence from studies on human tumours suggests that a similar situation exists
in man. Most malignant tumours undergo some degree of necrosis implying that
even intracellular antigens may be released. Why then are autoantibody
responses not more easily detected?
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Patient A.P. had only low levels of antibody activity at the time of operation
and peak titre was not achieved until some time after removal of the tumour.
It may be that antibody responses are commoner than is realised, but that because
oftheir timing are completely missed, or weak reactions detected about the time of
operation are ignored and not followed to their peak. The observation suggests
that as long as the tumour is in situ antibody will either be weak or undetectable
possibly because it is constantly absorbed by released tumour neoantigen. Such a
potential for in vivo absorption has been demonstrated with antibody to
renal glomerular antigens (Lerner et al., 1967). Further, the demonstration by
Lewis (1967) of the cytotoxicity of serum from individuals with non-metastatic
malignant melanomata on autologous melanoma cells yet its absence from those
persons with disseminated secondary deposits, may well represent the same
phenomenon.
A further factor possibly concerned in the rareness of detection of antibody
responses against tumour neoantigens concerns the antigen itself. Both antigens
described here are very heat labile. Many serological techniques are carried out
at 370 C. and it is possible therefore that some tumour neoantigens may be
inactivated during the course of the tests used in their detection. The use of a
complement fixation method with fixation at 40 C. overnight may avoid this loss
of antigenic activity.
The antigens reacting with the autoantibody have interesting properties.
Truly tumour specific antigens of human carcinoma breast have not previously
been described, but Loissillier et al. (1965) described an antigen of human carci-
noma breast which was also present in much lower concentration in normal breast.
The RNase-susceptible antigen of patient C.C. has a similar distribution. We
were however unable to demonstrate any reaction between serum A.P. and the
RNase-susceptible antigen using a tanned cell agglutination technique as used by
Loisillier and his colleagues. Although this casts doubt on the identity of these
two antigens the methods of antigen preparation were sufficiently different to
make any valid comparison very difficult.
The DNase-susceptible antigens appear to be completely tumour specific, even
absorption studies failing to reveal the antigen in normal breast tissue. The
antigen is closely associated with tumour nuclear material, is very heat labile, is
" soluble " and fixes complement well in the presence of antibody. These
characteristics are very similar to those ofthe T (tumour) antigens of DNA virus
induced animal tumours (Huebner et al., 1963; Black et al., 1963).
T antigens are believed to be either whole oncogenic virus genome in a partially
repressed state which does not allow the production of whole virus, or a portion
ofvirus genome in a form which permits its replication during cell division (Sabin,
1968). Ifthe DNase-susceptibleantigenisindeedaTantigenthenare some human
breast carcinomas virus induced? Tumour neoantigens in carcinogen induced
animal tumours are usually very specific for the tumour concerned (Klein and
Klein, 1962) and only rarely have two tumours been shown to have identical
neoantigens. Virus induced experimental tumours on the other hand possess
antigens which are virus specific; tumours induced by a particular oncogenic virus
all having similar antigens (Old and Boyse, 1965). Thus the finding in 6 of
11 specimens of carcinoma breast of apparently similar T-like antigens would
support the concept of a DNA-virus aetiology for some cases of human breast
carcinoma.
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